BBIO position history
The shares of Bridgebio Pharma (BBIO) that FARALLON CAPITAL MANAGEMENT, L.L.C. reported in each quarter’s 13F.
Shares held by quarter
New Add Reduce Exit
- 2023 Q4: 6,000 shares, $242K, <0.01% of portfolio, New
- 2024 Q1: not held, Exit
- 2024 Q2: not held
- 2024 Q3: 1,747,000 shares, $44M, 0.22% of portfolio, New
- 2024 Q4: 4,195,000 shares, $115M, 0.58% of portfolio, Add +140.1%
- 2025 Q1: 5,731,000 shares, $198M, 1.1% of portfolio, Add +36.6%
- 2025 Q2: 7,900,000 shares, $341M, 1.5% of portfolio, Add +37.8%
- 2025 Q3: 16,384,000 shares, $851M, 3.5% of portfolio, Add +107.4%
- 2025 Q4: 8,998,463 shares, $688M, 3.2% of portfolio, Reduce −45.1%
- 2026 Q1: 9,365,463 shares, $695M, 4.0% of portfolio, Add +4.1%
- 2026 Q2: 10,743,063 shares, $800M, 3.7% of portfolio, Add +14.7%
| Holdings date | Value | % of holdings | Shares | Filing date | All 13F holders |
|---|